FLAG Therapeutics Announces the Granting of Orphan Drug Designation to FLAG-003 in both the US and EU for the Treatment of Glioma

RALEIGH, N.C., March 1, 2016 -- (Healthcare Sales & Marketing Network) -- FLAG Therapeutics Inc. announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development and the European Medicines Agency (EMA) have both granted O... Biopharmaceuticals, Oncology, FDA, RegulatoryFLAG Therapeutics, FLAG-003, glioma, glioblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news